Metoprolol Medreg (Metoprolol Tartrate)

Metoprolol Medreg is a selective β1‑blocker used in several cardiovascular conditions.

• Hypertension: lowers systolic and diastolic pressure by reducing cardiac output.
• Angina pectoris: decreases myocardial oxygen demand, relieving chest pain.
• Post‑myocardial infarction: improves survival by limiting heart work and arrhythmias.
• Heart failure: enhances ventricular function and reduces hospitalisation risk.
• Cardiac arrhythmias: controls ventricular rate in atrial fibrillation and other tachyarrhythmias.

• Metoprolol Tartrate selectively antagonises β1‑adrenergic receptors on cardiac myocytes, inhibiting catecholamine‑induced stimulation of adenylate cyclase. This reduces intracellular cyclic AMP, leading to decreased calcium influx, lower myocardial contractility, slower heart rate, and reduced renin release, collectively diminishing cardiac output and arterial pressure.

Metoprolol Medreg may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Fatigue or tiredness
• Dizziness, especially on standing
• Cold extremities or reduced peripheral circulation
• Gastrointestinal upset such as nausea or abdominal discomfort
• Sleep disturbances or vivid dreams

Serious or Rare Side Effects

• Bradycardia (excessively slow heart rate)
• Severe hypotension (dangerously low blood pressure)
• Heart block or worsening heart failure
• Bronchospasm in patients with reactive airway disease
• Depression or mood changes

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor for adverse events.

• Cardiovascular assessment: review history of heart block, severe bradycardia, or decompensated heart failure.
• Respiratory evaluation: avoid in uncontrolled asthma or severe chronic obstructive pulmonary disease.
• Diabetes monitoring: watch for masking of hypoglycaemia symptoms.
• Concomitant drugs: adjust dose when used with other antihypertensives or negative‑chronotropic agents.
• Pregnancy and lactation: use only if potential benefit justifies potential risk; discuss with obstetrician.
• Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Metoprolol Medreg can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Non‑selective beta‑blockers or other negative‑chronotropic agents (e.g., verapamil, diltiazem) – may cause severe bradycardia or heart block.
• Potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine) – can increase metoprolol plasma levels and toxicity.

Moderate Interactions (Monitor Closely)

• Antihypertensive combinations (e.g., ACE inhibitors, diuretics) – may enhance hypotensive effect.
• Antidiabetic drugs (e.g., insulin, sulfonylureas) – may mask hypoglycaemia signs.
• NSAIDs or corticosteroids – may reduce antihypertensive efficacy.
• Calcium channel blockers (short‑acting) – may require dose adjustment.